CELCUITY INC. (CELC) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 86.87M USD | Liabilities, Current |
| Cash and equivalents | 182.05M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $86.87M | $182.05M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $33.21M | $145.19M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $44.15M | $165.70M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $38.79M | $74.25M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $39.94M | $46.35M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $32.92M | $16.48M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $31.72M | $22.51M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $26.31M | $12.60M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $19.53M | $30.46M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $16.70M | $31.21M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $14.19M | $30.66M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $12.71M | $25.76M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $7.08M | $32.24M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $5.81M | $33.64M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $6.88M | $24.57M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $6.65M | $57.48M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $4.15M | $66.91M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $3.55M | $78.30M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $2.51M | $84.29M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $2.82M | $90.37M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $1.54M | $41.64M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $1.17M | $34.94M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $1.19M | $11.64M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $1.04M | $13.70M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $828.88K | $15.43M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $864.95K | $16.85M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $911.33K | $18.74M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $912.09K | $16.27M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $885.49K | $14.92M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $882.15K | $14.72M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $662.33K | $15.94M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $960.61K | $3.81M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $962.89K | $3.17M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $783.03K | $2.57M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $578.05K | $2.64M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $336.45K | $32.30M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $10.91M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $4.90M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $445.36K | $5.86M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | $6.57M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $5.07M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |